US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rapport Therapeutics, Inc.

11.47

+0.02000.17%

Pre-market: 11.470.00000.00%04:22 EDT

Volume:119.81K

Turnover:1.35M

Market Cap:418.61M

PE:-3.04

High:11.75

Open:11.57

Low:10.99

Close:11.45

Loading ...

Overview Company News Filings

Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics initiated with an Outperform at Citizens JMP

Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting

Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares

Simply Wall St.

Top Executives Make Bold Moves with Major Stock Purchases!

Rapport Therapeutics Reports 2024 Financial Results and Progress

Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026

Rapport Therapeutics Inc trading resumes

Rapport Therapeutics Inc trading halted, volatility trading pause

Rapport Therapeutics Appoints New CMO Amid Phase 2a Updates

Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027

THOMSON REUTERS

Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

THOMSON REUTERS

Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus

Promising Clinical Trial Results and Stable Leadership Secure Buy Rating for Rapport Therapeutics

Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate

MT Newswires Live

Rapport Therapeutics announces new Phase 1 data for RAP-219

Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RAPP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RAPP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","market":"US","secType":"STK","nameCN":"Rapport Therapeutics, Inc.","latestPrice":11.47,"timestamp":1746129600000,"preClose":11.45,"halted":0,"volume":119811,"hourTrading":{"tag":"盘前","latestPrice":11.47,"preClose":11.47,"latestTime":"04:22 EDT","volume":4,"amount":46.32,"timestamp":1746174148162},"delay":0,"floatShares":14750261,"shares":36496437,"eps":-3.775953,"marketStatus":"Pre-Mkt","change":0.02,"latestTime":"05-02 05:40:35 EDT","open":11.57,"high":11.75,"low":10.99,"amount":1348895.7019,"amplitude":0.066376,"askPrice":14.54,"askSize":100,"bidPrice":8.33,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.775953,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746192600000},"marketStatusCode":1,"adr":0,"listingDate":1717732800000,"exchange":"NASDAQ","adjPreClose":11.47,"preHourTrading":{"tag":"盘前","latestPrice":11.47,"preClose":11.47,"latestTime":"04:22 EDT","volume":4,"amount":46.32,"timestamp":1746174148162},"postHourTrading":{"tag":"盘后","latestPrice":11.47,"preClose":11.47,"latestTime":"16:20 EDT","volume":912,"amount":10460.64,"timestamp":1746130802623},"volumeRatio":0.8279111736823662,"impliedVol":0.7198,"impliedVolPercentile":0.5596},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RAPP\",,,,,undefined,":{"symbol":"RAPP","floatShares":14750261,"roa":"-22.07%","roe":"-35.09%","lyrEps":-3.775953,"volumeRatio":0.8279111736823662,"shares":36496437,"dividePrice":0,"high":11.75,"amplitude":0.066376,"preClose":11.45,"low":10.99,"week52Low":6.43,"pbRate":"1.37","week52High":29.74,"institutionHeld":0,"latestPrice":11.47,"eps":-3.775953,"divideRate":0,"volume":119811,"delay":0,"ttmEps":-3.775953,"open":11.57,"prevYearClose":17.74,"prevWeekClose":10.62,"prevMonthClose":11.45,"prevQuarterClose":10.03,"fiveDayClose":11.1,"twentyDayClose":9.96,"sixtyDayClose":17.775},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RAPP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531033733","title":"Stifel Nicolaus Sticks to Its Buy Rating for Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531033733","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531033733?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:19","pubTimestamp":1746011968,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis reiterated a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) today and set a price target of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-sticks-to-its-buy-rating-for-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF"],"gpt_icon":0},{"id":"2525579538","title":"Rapport Therapeutics initiated with an Outperform at Citizens JMP","url":"https://stock-news.laohu8.com/highlight/detail?id=2525579538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525579538?lang=en_us&edition=fundamental","pubTime":"2025-04-08 16:56","pubTimestamp":1744102567,"startTime":"0","endTime":"0","summary":"Citizens JMP initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $28 price target Rapport is developing novel precision...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-an-outperform-at-citizens-jmp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-initiated-with-an-outperform-at-citizens-jmp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["JMP","RAPP","LENZ"],"gpt_icon":0},{"id":"2521462404","title":"Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2521462404","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521462404?lang=en_us&edition=fundamental","pubTime":"2025-03-21 19:00","pubTimestamp":1742554800,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, March 21, 2025  -- Rapport Therapeutics, Inc.  , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced two encore poster presentations at the 2025 American Academy of Neurology  Annual Meeting, taking place from April 5 to April 9, 2025, in San Diego, California. The data from these posters was originally presented at the American Epilepsy Society  Annual Meeting in December 2024.The presentations will highlight the company’s ongoing research and development of RAP-219, a clinical-stage AMPA receptor  negative allosteric modulator  currently in Phase 2 development for the treatment of refractory focal epilepsy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-present-data-2025-110000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZLL34.SGD","AES","AAN","LU1093756325.SGD","AFG","LENZ","BK4139","IE00B19Z3B42.SGD","BK4585","BK4178","BK4519","RAPP","BK4107","LU1093756168.USD","BK4105","LU0061475181.USD","IE00B19Z3581.USD","IE0002270589.USD","BK4117","BK4588"],"gpt_icon":0},{"id":"2519031674","title":"Insider Buying: Rapport Therapeutics Chief Financial Officer Bought US$101k Of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2519031674","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519031674?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:17","pubTimestamp":1742041039,"startTime":"0","endTime":"0","summary":"Investors who take an interest in Rapport Therapeutics, Inc.  should definitely note that the Chief Financial Officer, Troy Ignelzi, recently paid US$10.10 per share to buy US$101k worth of the stock. However, it only increased shareholding by a small percentage, and it wasn't a huge purchase by absolute value, either.Check out our latest analysis for Rapport Therapeutics. The Last 12 Months Of Insider Transactions At Rapport Therapeutics. Notably, that recent purchase by Troy Ignelzi is the biggest insider purchase of Rapport Therapeutics shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$10.51. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Rapport Thera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/insider-buying-rapport-therapeutics-chief-121719923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","RAPP","BK4139","BK4007"],"gpt_icon":0},{"id":"2519987815","title":"Top Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2519987815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519987815?lang=en_us&edition=fundamental","pubTime":"2025-03-14 10:09","pubTimestamp":1741918147,"startTime":"0","endTime":"0","summary":"New insider activity at Rapport Therapeutics, Inc. ( ($RAPP) ) has taken place on March 14, 2025. In recent transactions involving Rapport Therapeu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-executives-make-bold-moves-with-major-stock-purchases-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2518803984","title":"Rapport Therapeutics Reports 2024 Financial Results and Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2518803984","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518803984?lang=en_us&edition=fundamental","pubTime":"2025-03-12 12:14","pubTimestamp":1741752886,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has released its Q4 earnings. Here is a breakdown of the information Rapport Therapeutics, Inc. presented to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-reports-2024-financial-results-and-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LU2065732104.USD","PRGS","RAPP","BK4097","BK4007","BK4139"],"gpt_icon":0},{"id":"2518125097","title":"Rapport Therapeutics Q4 2024 GAAP EPS $(0.57) Beats $(0.62) Estimate, Ended the year with $305.3M in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2518125097","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518125097?lang=en_us&edition=fundamental","pubTime":"2025-03-11 19:10","pubTimestamp":1741691409,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.62) by 8.06 percent. This is a 92.88 percent increase over losses of $(8.01) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44242996/rapport-therapeutics-q4-2024-gaap-eps-0-57-beats-0-62-estimate-ended-the-year-with-305-3m-in-cash-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2516605335","title":"Rapport Therapeutics Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2516605335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516605335?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:30","pubTimestamp":1741102252,"startTime":"0","endTime":"0","summary":"10:29 EST Rapport Therapeutics (RAPP) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-resumes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","RAPP","LENZ","BK4139"],"gpt_icon":0},{"id":"2516058046","title":"Rapport Therapeutics Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2516058046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516058046?lang=en_us&edition=fundamental","pubTime":"2025-03-04 23:25","pubTimestamp":1741101957,"startTime":"0","endTime":"0","summary":"10:24 EST Rapport Therapeutics (RAPP) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-inc-trading-halted-volatility-trading-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","RAPP","BK4139","BK4007"],"gpt_icon":0},{"id":"2516638005","title":"Rapport Therapeutics Appoints New CMO Amid Phase 2a Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2516638005","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516638005?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:49","pubTimestamp":1741006147,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics, Inc. ( ($RAPP) ) has shared an announcement. On March 3, 2025, Rapport Therapeutics announced the appointment of Jeffrey Sevi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-appoints-new-cmo-amid-phase-2a-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rapport-therapeutics-appoints-new-cmo-amid-phase-2a-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4007","LENZ","RAPP"],"gpt_icon":0},{"id":"2516680974","title":"Rapport Therapeutics : Intends to Initiate Additional Phase 2a Trial of Rap-219 in Bipolar Mania in Q3 2025 With Topline Data Expected in H1 of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680974?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:17","pubTimestamp":1741004244,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RAPP","BK4007"],"gpt_icon":0},{"id":"2516994687","title":"Rapport Therapeutics Announces Appointment of DR. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2516994687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516994687?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA8F5FSW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0},{"id":"2516687647","title":"Press Release: Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2516687647","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516687647?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:00","pubTimestamp":1741003200,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development. In his role as CMO, Dr. Sevigny will oversee the development and execution of Rapport's clinical strategy and will be responsible for ensuring the advancement of Rapport's pipeline of precision medicines leveraging receptor associated protein  science. Building on the momentum of Rapport's RAP-219 program, his proven ability to advance clinical programs through late-stage clinical trials and regulatory approval will be instrumental in progressing RAP-219 and the broader pipeline.\"We are thrilled to welcome Jeff to Rapport. His extensive experience leading successful clinical development programs and driving drug development in neuroscience make him the ideal addition to our executive team and leader of our clinical development capability,\" said Abraham N. Ceesay, chief executive officer of Rapport. \"Jeff's proven ability in building e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","BK4516","BK4139","BK4588","RAPP","BK4007","BK4595","CNS","STRK","BK4585","BK4596","LENZ","BK4600","BK4023"],"gpt_icon":1},{"id":"2513401157","title":"Rapport Therapeutics to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2513401157","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513401157?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"BOSTON and SAN DIEGO, Feb. 24, 2025  -- Rapport Therapeutics, Inc. , a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system  disorders, today announced that management will present at two upcoming investor conferences in March 2025.TD Cowen 45th Annual Health Care Conference  – fireside chat on Tuesday, March 4, 2025, at 3:10-3:40pm EST.Stifel 2025 Virtual CNS Forum – fireside chat on Wednesday, March 19, 2025, at 10:30-10:55am EST.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rapport-therapeutics-participate-upcoming-investor-120000075.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CNS","BK4007","BK4135","LENZ","RAPP"],"gpt_icon":0},{"id":"2510825711","title":"Rapport Therapeutics, Inc. (RAPP) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510825711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510825711?lang=en_us&edition=fundamental","pubTime":"2025-02-11 12:27","pubTimestamp":1739248045,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday and set a price targe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rapport-therapeutics-inc-rapp-receives-a-buy-from-stifel-nicolaus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","SF","BK4127","RAPP"],"gpt_icon":0},{"id":"2502862363","title":"Promising Clinical Trial Results and Stable Leadership Secure Buy Rating for Rapport Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2502862363","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502862363?lang=en_us&edition=fundamental","pubTime":"2025-01-10 22:16","pubTimestamp":1736518568,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Justin Walsh has reiterated their bullish stance on RAPP stock, giving a Buy rating today. Justin Walsh has given his Buy rati...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-and-stable-leadership-secure-buy-rating-for-rapport-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-trial-results-and-stable-leadership-secure-buy-rating-for-rapport-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2502613855","title":"Stifel Nicolaus Remains a Buy on Rapport Therapeutics, Inc. (RAPP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502613855","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502613855?lang=en_us&edition=fundamental","pubTime":"2025-01-10 18:47","pubTimestamp":1736506028,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Rapport Therapeutics, Inc. (RAPP – Research Report) yesterday. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-rapport-therapeutics-inc-rapp?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RAPP","SF","BK4127","BK4007"],"gpt_icon":0},{"id":"2502988044","title":"Rapport Therapeutics Reports Positive Early Data for Epilepsy Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2502988044","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502988044?lang=en_us&edition=fundamental","pubTime":"2025-01-10 00:44","pubTimestamp":1736441063,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics  said Thursday that preliminary analysis of data from positron emission tomography and the second multiple ascending dose trials for RAP-219 showed it achieved target receptor occupancy within five days of dosing.The investigational drug also maintained a differentiated tolerability profile, according to the company.The company is evaluating RAP-219 in patients with refractory focal epilepsy in a phase 2a proof-of-concept trial and expects topline results in mid-2025.Price: 16.69, Change: -1.10, Percent Change: -6.16","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","RAPP"],"gpt_icon":0},{"id":"2502011580","title":"Rapport Therapeutics announces new Phase 1 data for RAP-219","url":"https://stock-news.laohu8.com/highlight/detail?id=2502011580","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502011580?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:20","pubTimestamp":1736425214,"startTime":"0","endTime":"0","summary":"Rapport Therapeutics (RAPP) announced results from its positron emission tomography trial and second multiple ascending dose trial for RAP-219. Dat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-new-phase-1-data-for-rap-219?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/rapport-therapeutics-announces-new-phase-1-data-for-rap-219?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","RAPP"],"gpt_icon":0},{"id":"2502361015","title":"Rapport Therapeutics Inc - Phase 2a Trial of Rap-219 on Track, Data Expected Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2502361015","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502361015?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:00","pubTimestamp":1736424000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250109:nTUA6FRQX5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RAPP"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":39,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RAPP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-11","symbol":"RAPP","fiscalQuarterEnding":"2024/12","expectedEps":-0.62,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.57},{"market":"US","date":"2024-11-07","symbol":"RAPP","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RAPP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RAPP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1744171200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RAPP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RAPP","date":"2025-04-30","current":-5.152389,"percent":0.809756,"low":-18.456468,"twenty":-13.694662,"median":-10.655158,"eighty":-5.303861,"high":-1.238107,"avg":-10.041998,"sd":4.099032,"marketCap":403468111},"quantilePoints":[{"date":"2024-06-07","current":-11.721364,"twenty":-11.721364,"median":-11.721364,"eighty":-11.721364,"marketCap":601399769},{"date":"2024-06-14","current":-15.892791,"twenty":-16.325792,"median":-15.672154,"eighty":-13.81742,"marketCap":815427333},{"date":"2024-06-21","current":-15.811683,"twenty":-18.036085,"median":-15.892791,"eighty":-15.139866,"marketCap":811265816},{"date":"2024-06-28","current":-16.346343,"twenty":-18.021611,"median":-15.892791,"eighty":-15.672154,"marketCap":838698159},{"date":"2024-07-05","current":-16.610109,"twenty":-18.028848,"median":-16.581593,"eighty":-15.672154,"marketCap":852231448},{"date":"2024-07-12","current":-18.456468,"twenty":-18.064817,"median":-16.682383,"eighty":-15.783777,"marketCap":946964471},{"date":"2024-07-15","current":-18.299635,"twenty":-18.092899,"median":-16.754656,"eighty":-15.811683,"marketCap":938917651},{"date":"2024-08-02","current":-14.614044,"twenty":-18.085878,"median":-16.682383,"eighty":-15.70006,"marketCap":749817368},{"date":"2024-08-09","current":-10.772462,"twenty":-18.050559,"median":-16.581593,"eighty":-14.719551,"marketCap":678859041},{"date":"2024-08-16","current":-11.828814,"twenty":-17.877609,"median":-15.852237,"eighty":-12.152035,"marketCap":745428193},{"date":"2024-08-23","current":-12.310557,"twenty":-17.253126,"median":-15.672154,"eighty":-12.113216,"marketCap":775786652},{"date":"2024-08-30","current":-11.492174,"twenty":-17.046391,"median":-14.856424,"eighty":-11.831136,"marketCap":724213848},{"date":"2024-09-06","current":-12.316361,"twenty":-16.995064,"median":-14.477739,"eighty":-11.828814,"marketCap":776152417},{"date":"2024-09-13","current":-10.975607,"twenty":-16.754656,"median":-13.041877,"eighty":-11.712731,"marketCap":691660801},{"date":"2024-09-20","current":-11.75336,"twenty":-16.610109,"median":-12.73716,"eighty":-11.45735,"marketCap":740673254},{"date":"2024-09-27","current":-11.915876,"twenty":-16.610109,"median":-12.415031,"eighty":-11.492174,"marketCap":750914662},{"date":"2024-10-04","current":-10.644772,"twenty":-16.581593,"median":-12.319263,"eighty":-11.45735,"marketCap":670812221},{"date":"2024-10-11","current":-11.846226,"twenty":-16.346343,"median":-12.304752,"eighty":-11.439937,"marketCap":746525487},{"date":"2024-10-18","current":-16.28058,"twenty":-16.346343,"median":-12.319263,"eighty":-11.45735,"marketCap":1025969618},{"date":"2024-10-25","current":-14.411651,"twenty":-16.28058,"median":-12.415031,"eighty":-11.492174,"marketCap":908193427},{"date":"2024-10-31","current":-15.578281,"twenty":-15.970349,"median":-12.705237,"eighty":-11.650047,"marketCap":981712105},{"date":"2024-11-08","current":-13.694662,"twenty":-15.827905,"median":-12.870655,"eighty":-11.708088,"marketCap":983906693},{"date":"2024-11-15","current":-11.189913,"twenty":-15.754653,"median":-12.798103,"eighty":-11.650047,"marketCap":803950524},{"date":"2024-11-22","current":-11.464825,"twenty":-15.685802,"median":-12.664608,"eighty":-11.434133,"marketCap":823701811},{"date":"2024-11-29","current":-11.627735,"twenty":-15.672154,"median":-12.397619,"eighty":-11.395825,"marketCap":835406277},{"date":"2024-12-06","current":-10.319361,"twenty":-15.61583,"median":-12.322165,"eighty":-11.357915,"marketCap":741404783},{"date":"2024-12-13","current":-9.677901,"twenty":-15.33799,"median":-12.307654,"eighty":-11.16344,"marketCap":695318447},{"date":"2024-12-20","current":-9.092441,"twenty":-15.121845,"median":-12.218286,"eighty":-11.007144,"marketCap":653255522},{"date":"2024-12-27","current":-9.815356,"twenty":-15.075412,"median":-12.095804,"eighty":-10.933817,"marketCap":705194090},{"date":"2025-01-03","current":-9.362262,"twenty":-15.053587,"median":-12.072587,"eighty":-10.78291,"marketCap":672641044},{"date":"2025-01-10","current":-8.4968,"twenty":-15.021085,"median":-11.886855,"eighty":-10.451725,"marketCap":610461067},{"date":"2025-01-17","current":-6.368782,"twenty":-15.009476,"median":-11.834618,"eighty":-10.309179,"marketCap":457571477},{"date":"2025-01-24","current":-7.264789,"twenty":-14.781954,"median":-11.796891,"eighty":-9.793974,"marketCap":521946041},{"date":"2025-01-31","current":-8.476436,"twenty":-14.660068,"median":-11.755009,"eighty":-9.580154,"marketCap":608998009},{"date":"2025-02-07","current":-8.527345,"twenty":-14.639173,"median":-11.73446,"eighty":-9.397898,"marketCap":612655654},{"date":"2025-02-14","current":-8.028432,"twenty":-14.630244,"median":-11.689515,"eighty":-9.145387,"marketCap":576810726},{"date":"2025-02-21","current":-6.618238,"twenty":-14.619747,"median":-11.627735,"eighty":-9.042041,"marketCap":475493941},{"date":"2025-02-28","current":-5.467683,"twenty":-14.492608,"median":-11.461087,"eighty":-8.488654,"marketCap":392831148},{"date":"2025-03-07","current":-4.11349,"twenty":-14.373344,"median":-11.410917,"eighty":-8.297234,"marketCap":295537772},{"date":"2025-03-14","current":-4.670008,"twenty":-14.343983,"median":-11.35537,"eighty":-8.022323,"marketCap":365694298},{"date":"2025-03-21","current":-4.716615,"twenty":-14.310432,"median":-11.296823,"eighty":-7.313662,"marketCap":369343942},{"date":"2025-03-28","current":-4.520866,"twenty":-14.209667,"median":-11.0932,"eighty":-7.051987,"marketCap":354015438},{"date":"2025-04-04","current":-3.970905,"twenty":-14.097067,"median":-11.027844,"eighty":-6.777076,"marketCap":310949643},{"date":"2025-04-11","current":-4.022172,"twenty":-13.848651,"median":-10.975607,"eighty":-6.460419,"marketCap":314964251},{"date":"2025-04-17","current":-4.54883,"twenty":-13.703476,"median":-10.88248,"eighty":-6.145798,"marketCap":356205225},{"date":"2025-04-25","current":-5.173362,"twenty":-13.694662,"median":-10.772462,"eighty":-5.351373,"marketCap":405110450},{"date":"2025-04-30","current":-5.152389,"twenty":-13.694662,"median":-10.655158,"eighty":-5.303861,"marketCap":403468111}],"updateTime":1746137996627}}}